These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 24382098)

  • 1. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.
    Ramirez L; Corvo L; Duarte MC; Chávez-Fumagalli MA; Valadares DG; Santos DM; de Oliveira CI; Escutia MR; Alonso C; Bonay P; Tavares CA; Coelho EA; Soto M
    Parasit Vectors; 2014 Jan; 7():3. PubMed ID: 24382098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
    Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
    Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.
    Soto M; Corvo L; Garde E; Ramírez L; Iniesta V; Bonay P; Gómez-Nieto C; González VM; Martín ME; Alonso C; Coelho EA; Barral A; Barral-Netto M; Iborra S
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003751. PubMed ID: 25955652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers.
    Iborra S; Abánades DR; Parody N; Carrión J; Risueño RM; Pineda MA; Bonay P; Alonso C; Soto M
    Clin Exp Immunol; 2007 Nov; 150(2):375-85. PubMed ID: 17900304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge.
    Ramírez L; Iborra S; Cortés J; Bonay P; Alonso C; Barral-Netto M; Soto M
    J Biomed Biotechnol; 2010; 2010():181690. PubMed ID: 20145701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
    Chávez-Fumagalli MA; Costa MA; Oliveira DM; Ramírez L; Costa LE; Duarte MC; Martins VT; Oliveira JS; Olortegi CC; Bonay P; Alonso C; Tavares CA; Soto M; Coelho EA
    Microbes Infect; 2010 Nov; 12(12-13):967-77. PubMed ID: 20601076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
    Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
    Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
    Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
    Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice.
    Iborra S; Parody N; Abánades DR; Bonay P; Prates D; Novais FO; Barral-Netto M; Alonso C; Soto M
    Microbes Infect; 2008; 10(10-11):1133-41. PubMed ID: 18603012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.
    Duarte MC; Lage DP; Martins VT; Costa LE; Carvalho AMRS; Ludolf F; Santos TTO; Vale DL; Roatt BM; Menezes-Souza D; Fernandes AP; Tavares CAP; Coelho EAF
    Immunobiology; 2017 Feb; 222(2):251-260. PubMed ID: 27693018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Leishmanization Using
    Keshavarzian N; Noroozbeygi M; Haji Molla Hoseini M; Yeganeh F
    Front Immunol; 2020; 11():1725. PubMed ID: 33193290
    [No Abstract]   [Full Text] [Related]  

  • 13. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
    Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
    Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.
    Badiee A; Jaafari MR; Samiei A; Soroush D; Khamesipour A
    Clin Vaccine Immunol; 2008 Apr; 15(4):668-74. PubMed ID: 18235040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.
    Santos DM; Carneiro MW; de Moura TR; Fukutani K; Clarencio J; Soto M; Espuelas S; Brodskyn C; Barral A; Barral-Netto M; de Oliveira CI
    Int J Nanomedicine; 2012; 7():2115-27. PubMed ID: 22619548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis.
    Carneiro MW; Santos DM; Fukutani KF; Clarencio J; Miranda JC; Brodskyn C; Barral A; Barral-Netto M; Soto M; de Oliveira CI
    PLoS One; 2012; 7(12):e52296. PubMed ID: 23284976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
    Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with Leishmania infantum acidic ribosomal P0 but not with nucleosomal histones proteins controls Leishmania infantum infection in hamsters.
    Pereira L; Abbehusen M; Teixeira C; Cunha J; Nascimento IP; Fukutani K; dos-Santos W; Barral A; de Oliveira CI; Barral-Netto M; Soto M; Brodskyn CI
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003490. PubMed ID: 25642946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.